Viral-based immunotherapies to transform the fight against cancers and infectious diseases. November 2017 Corporate Presentation
|
|
- Andrea Rogers
- 6 years ago
- Views:
Transcription
1 Viral-based immunotherapies to transform the fight against cancers and infectious diseases November 2017 Corporate Presentation
2 Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii) regulatory authorities will agree with the Company s further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company s activities, perspectives, financial situation, results and development. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ( Facteurs de Risque") section of the Document de Référence, available on the AMF website ( or on Transgene s website ( Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forwardlooking statements, even if new information becomes available in the future. 2
3 Management Experienced team focused on delivery Philippe Archinard, PhD Chairman & Chief Executive Officer Eric Quéméneur, PhD Executive VP and Chief Scientific Officer E C Christophe Ancel, PharmD VP Quality and Qualified Person Maud Brandely, MD, PhD Chief Medical Officer A B C D E F A B D Jean-Philippe Del VP Finance Thibaut du Fayet, MBA VP Marketing, Alliance, and Project Mgt John Felitti, JD, MBA General Counsel and VP Legal F Hemanshu Shah, PhD, MBA VP Corporate Development & Medical Affairs 3
4 Transgene Poised to play a key role in immunotherapy A pioneer in developing viral vector-based immunotherapies Focus on cancers and infectious diseases: High level of unmet medical need New treatments leave significant opportunities 2 Cutting-edge immunotherapy platforms Therapeutic vaccines Oncolytic viruses 5 Immunotherapy products in clinical trials focus on combinations 4
5 ORR % Anti-PD-1/PD-L1 A new paradigm need for improvement Targeting substantial non-responder populations Transgene s indications of interest 100 Non-responders 50 0 FDA approved agent available ORR = approximate objective response rate % Source: from ASCO Annual meeting 2017, by Gregory L. Beatty, MD PhD *Anti-PD-1 FDA approved in Sept
6 The power of immunotherapy combinations Strong scientific rationale for adding our immunotherapies to ICIs Immune Checkpoints Inhibitors (ICIs) Transgene s immunotherapies Block the signal that prevents activated T-cells from attacking cancer cells Enhance the efficacy of anti-tumor T-cell response Need for increased response rate Therapeutic Vaccines Stimulate the immune response to kill cancer cells Oncolytic Viruses Directly attack tumor cells and boost the immune system Safety - Preserve healthy cells Compelling preclinical and clinical packages Increased response rate, longer duration of response, extended OS Positive effects of the combination of Transgene s immunotherapies with ICIs have been demonstrated in several preclinical tumor models 6
7 Transgene Building momentum in immuno-oncology Clinical collaborations validate the potential of ICI+TG immunotherapy combinations Clinical collaborations made possible by Transgene s compelling clinical and pre-clinical packages Refocused clinical development on combination trials with ICIs Oct 2016 Clinical collaboration for TG4001 Apr 2017 Clinical collaboration for TG4010 (NSCLC 1L) 7 clinical trials initiated in last 18 months Readouts expected on 5 products Dec 2016 Clinical collaboration for TG4010 (NSCLC 2L) Jun 2017 Research collaboration agreement for UCART-19 production Sep 2017 Launch OV platform for a new generation OV 7
8 Diversified portfolio of clinical-stage immunotherapies Product THERAPEUTIC VACCINES Indication Preclinical Clinical Phase Major Expected Milestones Non-small cell lung cancer 1 st line + nivolumab (ICI) + CT FPI YE17 TG4010 Non-small cell lung cancer 2 nd line + nivolumab (ICI) First data 1Q 2018 Non-small cell lung cancer Neo-adjuvant (translational) TG4001 HPV positive cancers + avelumab (ICI) First data in 2H 18 TG1050 Chronic hepatitis B + antiviral Full data in 1H 18 ONCOLYTIC VIRUSES HCC 1 st line (PHOCUS) + sorafenib First data 2019 Pexa-Vec* HCC 1 st line Other solid tumors + nivolumab (ICI) + ipilimumab (ICI) First data in 2H 2018 Sarcoma Breast cancer + cyclophosphamide Solid tumors Neo-adjuvant (translational) TG6002 Glioblastoma First data in 2H 18 Ongoing FPI < 6 months * Transgene has commercial rights to Pexa-Vec in Europe and additional selected countries. SillaJen has a co-promote option in five European countries. 8
9 Therapeutic Vaccines Ideally suited for combination immunotherapy regimens
10 Our Therapeutic Vaccine platform Therapeutic vaccines express tumor/viral antigens To stimulate a safe and specific immune response Antigen (MUC1) expression leading to maturation of Antigen Presenting Cell (APC) Mature APCs present MUC1 antigen to naive T-cells SC injection T-cells get activated, multiply and reach the blood stream Important benefit when combined with CT and ICIs Activated T-cells infiltrate the tumor, recognize and kill MUC1+ tumor cells 10
11 TG4010 targeting 1 st and 2 nd line NSCLC Modified Virus Ankara (MVA) expressing MUC1 antigen & interleukin 2 Clinical collaborations with
12 TG4010 Strong lung cancer clinical data Improved response rate & duration of response TG4010 TG chemotherapy (n=39) [23.9 [ ] 54.1] wks wks Non-squamous (n) ORR Median duration of response (wks) TG CT 98 40% 41 Placebo + CT 98 28% 18 Placebo Chemotherapy + chemotherapy (n=27) 18.1 [ ] wks Improved response rate & duration of response Good safety profile Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 12
13 TG4010 Strong lung cancer clinical data Well positioned for further development in NSCLC SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS) TG4010 in combination with chemotherapy for 1 st line NSCLC Progression-free survival (months) Patients with non sq. tumors (n=196) Overall survival (months) Patients with non sq. tumors (n=196) Significant improvements in PFS and OS in patients in patients with non sq. tumors TG chemotherapy Placebo + chemotherapy 35% 19% TG chemotherapy Placebo + chemotherapy 36% 20% Clinical efficacy in both PD-L1 negative and PD-L1 positive patients Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 13
14 TG4010 Proven mechanism of action Efficacy driven by T-cell response (CD8+) Specific CD8+ T cell response to MUC1 epitopes is associated with increased survival OS improvement during TG4010 treatment is driven by the development of a larger CD8+ T cell anti-muc1 repertory Specific CD8+ T cell response to MUC1 after TG4010 administration is associated with responses against other lung tumor antigens Increased CD8+ response without increase in inhibitory T reg frequency Source: Tosch et al., Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC, Journal for ImmunoTherapy of Cancer, 2017 (5:70) 14
15 TG4010 Clinical positioning A very large population in NSCLC, stage IV, non-squamous patients Eligible Population (US, EU, JP), in thousands of patients STAGE IV 710 K NON-SQUAMOUS NON-MUTATED (ALK, EGFR, ) 441 K 532 K 1L - TG4010 positioning 2L - TG4010 positioning LOW PD-L1-1ST LINE 2ND LINE (INDEPENDENT OF PD-L1 STATUS) 265 K 331 K Source: Globocan, Company estimates 15
16 TG4010 Clinical development plan (non sq. NSCLC) 2 PoC trials to demonstrate the efficacy of TG4010 combined with ICIs Position TG4010 in all settings of advanced NSCLC in combination with PD-1 inhibitor NSCLC - 2 nd line TG PD-1 Inhibitor (nivolumab) Multi-center Phase 2 trial in the US PI: Dr. Karen Kelly (UC Davis) BMS to supply nivolumab First data expected 1Q 2018 NSCLC - 1 st line patients with no or low level of PD-L1 expression TG chemotherapy + PD-1 Inhibitor (nivolumab) Multi-center Phase 1/2 trial in US and Europe BMS to supply nivolumab US FDA IND approval granted (Sept. 2017) FPI expected to be enrolled end 2017 First data expected in 2H
17 TG4010 Non-Small Cell Lung Cancer (NSCLC) - 2 nd line Phase 2 in combination with Opdivo (nivolumab) Support of Protocol Up to 33 patients Multi-center, single-arm, open-label study Stage IV non-squamous NSCLC who have progressed after one line of systemic therapy Principal Investigator: Dr. Karen Kelly Collaborative arrangement UC Davis Medical Center, USA (sponsor) Bristol-Myers Squibb (supply of nivolumab) Transgene (supply of TG4010) First patient treated in March 2017 First planned data expected 1Q 2018 (15 patients) Endpoints Primary endpoint: Objective response rate (ORR) Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response and safety Participating centers UC Davis UC San Francisco City of Hope UC San Diego 17
18 TG4010 Non-Small Cell Lung Cancer (NSCLC) - 1 st line Phase 1/2 in combination with Opdivo (nivolumab) + chemotherapy Support of Collaborative agreement with BMS (supply of nivolumab) US FDA IND Approval (Sept. 2017) First patient expected to be enrolled by the end of 2017 First data expected in 2H 2018 Study regimen TG PFU weekly for 6 weeks then every 3 weeks by SC route Nivolumab 360 mg every 3 weeks by IV route Pemetrexed-carboplatin (or cisplatin) every 3 weeks for 4 cycles Protocol Up to 39 patients Multi-center, single-arm, open-label study Stage III B-IV or delayed relapse, tumors with low or undetectable PD-L1 expression Endpoints (Phase 2 part) Primary endpoint: Objective response rate (ORR) Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response and safety Participating countries USA Belgium Denmark France 18
19 TG4001 targeting HPV-positive head and neck cancer MVA expressing HPV16 E6 & E7 antigens & interleukin 2 Supported by
20 TG4001 No specific treatment regimens for HPV+ head and neck cancer patients ~60% of oropharyngeal SCCHN are HPV+ Increasing incidence in western countries 25,000 patients* Dismal prognosis Much better therapeutic options needed Current treatment options for all head and neck cancer cases First-line therapy For patients with good performance status: historically platinum-based doublet (e.g. Cisplatin/5-FU or carboplatin/paclitaxel) ORR: 30% to 40% Median OS: 6-9 months regardless of specific drug For patient with poor performance status: use single agent CT or cetuximab Second-line therapy Nivolumab, pembrolizumab ORR: 16% to 19% Median OS: 7-8 months Significant opportunity for TG4001 to improve the ORR of ICIs in a large head and neck cancer population * Source: Globocan, Company estimates 20
21 TG4001 Strong rationale for combining a vaccine targeting HPV with an ICI in advanced/metastatic HPV-positive SCCHN TG already demonstrated efficacy in the clinic: Randomized, placebo-controlled Phase 2b (n=206) in HPV+ high grade cervical carcinoma in situ (CIN2/3) Demonstrated immunogenicity Demonstrated efficacy (resolution and viral clearance) Study confirmed safety (injection site reaction most common adverse event) TG4001 was nevertheless not progressed further in CIN 2/3 (LEEP efficacy) Thanks to KOLs and Merck KGaA/Pfizer s commitment, decision to progress rather in advanced HPV positive cancers in combination with avelumab Very strong scientific rationale for combining TG4001 and avelumab to address the high unmet medical in this important HPV-positive cancer population 21
22 TG4001 HPV + Head & Neck Cancers (SCCHN) On-going Phase 1b/2 in combination with avelumab (Bavencio ) Support of Protocol Up to 50 patients (France) Multi-center, single-arm, open-label trial Metastatic or refractory/recurrent HPV-16+ head & neck cancers, after failure of standard therapy Lead investigator: Prof Christophe Le Tourneau, Institut Curie Collaborative agreement with the alliance of Merck KGaA and Pfizer (supply of avelumab) First patient treated in September 2017 Endpoints (Phase 2 part) Primary endpoint: Objective response rate (ORR) Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response and safety First data expected in 2H
23 TG1050 targeting chronic hepatitis B Modified Adenovirus 5 that expresses 3 different HBV (Hepatitis B Virus) antigens
24 TG1050 Current therapies focus on disease management, not cure Large unmet medical need as cure rate is extremely low Need to improve clinical outcome: High risk of developing cirrhosis and hepatocellular carcinoma 500,000 eligible patients* Treatment recommendations (EASL 2017 clinical guidelines) Long-term administration of entecavir (Baraclude ), tenofovir disoproxil fumarate (Viread ) or tenofovir alafenamide (Vemlidy ) as monotherapy High level of viral suppression 98 % Low level of functional cure (HBsAg loss) < 3 % per year PegIFN for 48 weeks in highly selected patients Moderate level of viral suppression 50 % Low level of functional cure < 9% per year * Source: Decision Resources, Company estimates Note: Includes patients from the US, EU, and Japan 24
25 HBsAg Fold Change (Mean +/- SEM) HBV DNA Fold Change (Mean +/- SEM) TG1050 Strong pre-clinical data Sustained anti-viral effects in HBV mouse models (AAV) Only viral-based therapeutic vaccine that integrates the 3 relevant HBV antigens (polymerase, core, HBsAg) Demonstrated immunogenicity & functionality Similar to those of spontaneous resolvers i.e. robust and broad CD8 T-cell responses Capacity of HBV-specific T cells induced by TG1050 to recognize epitopes all HBV genotypes Capacity to induce functional T-cells in tolerant HBV mouse models (Novel AAV-based model, other) Antiviral properties Capacity to control HBsAg and induce HBsAg seroconversion with no detectable liver inflammation in tolerant HBV mouse models Ongoing preclinical experiments (direct/indirect antivirals, immunomodulators, ) HBV DNA (viral load) Mean viral load at D28 : 1.4x106 copies/ml Empty Ad TG1050 Days post AAV-HBV injection Circulating HBsAg Mean HBsAg titers at D28 : 20µg/mL Empty Ad TG Days post AAV-HBV injection Martin et al., Gut, 2014 Inschauspé et al., EASL,
26 TG1050 Phase 1/1b trial Principal investigator Prof Fabien Zoulim, Hospices civils, Lyon (France) Protocol Up to 48 patients International, randomized safety and dosefinding study Patients currently being treated with standard-of-care antiviral therapy (tenofovir or entecavir) Initial safety data in 12 patients reported First efficacy data expected 1H 2018 (n=48) Participating countries Canada, France, Germany Primary objectives Evaluate safety and tolerability of TG1050 administered in single and multiple doses (3 injections at one week interval) Determine dose and schedule of administration for further development Secondary endpoints Antiviral activity: HBsAg levels Cellular and humoral immune responses Phase I/Ib enrolment completed Preliminary data (AASLD Liver Meeting 2017): Good safety profile in 12 patients TG1050 induces a robust specific cell-mediated immune response in patients that have received a single dose of TG
27 Oncolytic Viruses Pioneered by Transgene A new highly promising therapeutic class in the fight against cancer
28 Our Oncolytic Virus (OV) platform IT/IV administration to directly attack tumor cells and stimulate immune response OV infect tumor cells where they selectively replicate This replication leads to immunogenic cell death, virus propagation in neighboring cells and in situ vaccination Active payloads are expressed locally and released into the tumor micro-environment Cytotoxic T-cells enter into the tumor, attracted by local inflammation and danger signals Infiltrated T-cells kill tumor cells and boost anti-tumor response by active release of tumor antigens Preclinical models show OV s ability to reduce tumor burden and have an abscopal effect on distant metastasis via induced immunogenic cell death mechanism 28
29 Pexa-Vec in hepatocellular carcinoma (HCC) Replicative Vaccinia Virus expressing GM-CSF
30 Pexa-Vec Collaboration with SillaJen Transgene owns development and commercialization rights in Europe EU rights of Pexa-Vec in-licensed in 2010 Current licensor: SillaJen (KOSDAQ: ) Ongoing pivotal Phase 3 trial in HCC 1L SillaJen responsible for conducting Phase 3 trial Transgene own all rights for its territory Transgene s remaining funding obligation amounts to $1.5 million 4 Phase 2 trials conducted by Transgene 30
31 Pexa-Vec Large unmet medical need in HCC Dismal prognosis Better therapeutic options needed 25,000 eligible patients in Europe* First-line therapy Sorafenib is currently the only approved product - modest activity ORR: 2% ; median OS: 10.7 months Nivolumab could become a new therapeutic option: Promising activity in Phase 2 (still ongoing) Second-line therapy Regorafenib ORR: 10%; median OS: 10.6 months Nivolumab recently approved by FDA ORR: 18%; median OS: 15.6 months * Source: Globocan, Company estimates 31
32 Pexa-Vec Key Phase 2 clinical trial results Clinical activity demonstrated in multiple trials Trials with >300 patients treated with Pexa-Vec in variety of tumor types, including liver, colorectal and kidney Proof of concept for MOA: active immunotherapy 30-patient dose-finding Phase 2 trial in HCC (80% of patients first-line) OS results - high dose versus low dose Median OS: 14.1 (high dose) vs. 6.7 months (low dose) Hazard Ratio = 0.39 p = Nature Medicine, Volume 19, Issue 2, February
33 Pexa-Vec Clinical development plan in HCC - 1 st line Pivotal Phase 3 and combination Phase 2 Position Pexa-Vec with SoC treatment for all PD-L1 status patients Advanced HCC 1 st line Advanced HCC 1 st line Pexa-Vec + sorafenib Pexa-Vec + Opdivo (nivolumab) Multi-center Phase 3 trial in Europe, US, Asia Randomized, two arm trial Ongoing recruitment First data (efficacy vs SoC) expected in 2019 Multi-center Phase 1/2 trial in France, Italy, US Sponsor: Transgene Open-label, single-arm trial 1 st patient dosed in July 2017 Efficacy data expected in 2H
34 Pexa-Vec Ongoing Phase 3 clinical trial (PHOCUS trial) 1 st line advanced hepatocellular carcinoma Phase 3 study in combination with sorafenib (Kinase inhibitor) Design Pexa-Vec + sorafenib versus sorafenib (only approved drug for advanced HCC) N= 600 patients (Europe, North America, and Asia), 140 clinical centers 1:1 randomized trial Conducted by Endpoints Primary: overall survival (OS) Secondary: safety, time to progression, progression-free survival, overall response rate and disease control rate Orphan drug designation granted SPA with FDA SFDA authorization (July 2017) First patient enrolled in January 2016 Recruitment ongoing First efficacy data expected in
35 Pexa-Vec Phase 1/2, combo with nivolumab Advanced stage HCC - 1 st line Principal Investigator: Prof Olivier Rosmorduc, Pitié-Salpêtrière Hospital, Paris (France) First patient treated in July 2017 Study regimen Pexa-Vec: 3 intratumoral injections, 10 9 pfu, q2w +/- boosts Nivolumab: IV, 240mg, q2w until progression, start at D15 Protocol Up to 36 patients Multi-center, open label trial Patients with advanced-stage HCC, treatment naive Participating countries France, Italy, US Endpoints (Phase 2 part) Primary endpoint: Objective response rate (ORR) Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response and safety Exploratory endpoints: extended translational program (PDL1 ) including biopsy during treatment Efficacy data expected in 2H
36 Oncolytic viruses Our clear roadmap for success FUTURE GENERATIONS Level of innovation Imlygic/T-Vec, Pexa-Vec Oncolytic activity IT administration Indirect immune stimulation, via non-specific immune modulators (e.g. GM-CSF) NEW GENERATION TG6002 Oncolytic activity Systemic (IV) administration Better tumor selectivity (double gene deletion) Additional functionality - targeted chemotherapy Oncolytic activity Systemic (IV) administration Better tumor selectivity (double gene deletion) Armed targeted immune modulators expressed in tumor microenvironment Time to market 36
37 TG6002 First product incorporating our newest vector Improved virus and advanced therapeutic payload Superior oncolytic properties with local production of chemotherapy Proprietary virus Double gene deletion TK- RR- Viral oncolysis Targeted chemotherapy FCU1 gene Prodrug 5-FC Prodrug activating enzyme Cytotoxic drug 5-FU Cell death Phase 1 trial in glioblastoma, open label, dose escalation, IV administration PI: Prof A. Idbaih, MD, PhD (Pitié Salpêtrière Hospital, France) INCA Grant First data in 2H 18 First-in-human trial 1 st patient treated in Oct Development in GI cancers in active preparation 37
38 Significant anticipated value-creating news flow through 2018 Clinical readouts expected on all 5 products TG4010 Lung cancer (NSCLC) First Phase 2 data 1Q 2018 (2 nd line, TG nivolumab) 5 products in the clinic TG4001 TG1050 Pexa-Vec HPV+ head & neck cancer (SCCHN) Chronic hepatitis B (HBV) Liver cancer (HCC) First Phase 2 data in 2H 2018 (TG avelumab) Full Phase 1b data in 1H 2018 Phase 2 efficacy data in 2H 2018 (Pexa-Vec + nivolumab) TG6002 Glioblastoma First Phase 1 data 2H
39 Appendices 39
40 Company funded to deliver multiple value generating milestones Key figures Key shareholders As of September 30, 2017 ~ 30 million ~ 5 million 40 million Expected cash burn 2017 (~ 14 million for 4Q 2017) Operating revenues as of September 30, 2017 Cash and cash equivalents as of September 30, % Free float 40 % 10 million drawn down (Due 2021) Market capitalization: ~ 200 million as of September 30, million shares outstanding million options and restricted stocks Listed on Euronext Paris ISIN: FR Ticker: TNG 40
41 Our strategy Develop future disruptive innovation Engineer multifunctional oncolytic viruses Patented Viruses Anti-cancer Weapons VV TK - RR - + Enzyme Antibody SdAb Cytokines / Chemokines Receptor ligands Oncolytic activity Immunogenic properties Tumor targeting from the IV route Key effectors of the tumor microenvironment Potent immunomodulators benefiting from local delivery 41
42 Our strategy Develop future disruptive innovation Engineer viruses that attack the tumor at multiple points Cellular Improved replication in resistant tumor cells Improved lytic activity + release of immunogenic components Tumor microenvironment Attraction + infiltration of effector immune cells Breakdown of immunosuppressive mechanisms Organism Mobilization of innate + adaptive responses Systemic efficacy 42
43 ICI clinical collaboration scheme General approach Proof-of-concept trials Collaborative design of the protocol with shared expectations for outcomes Open-label trials with joint access to results No preferential rights granted over TG4010 or TG4001 Partner to provide ICI for the trial and participate in clinical sites selection Transgene to provide its product, fund the trials and ensure their execution 3 ongoing clinical collaborations TG4010, 1L, advanced lung cancer TG4010, 2L, advanced lung cancer TG4001, 2L, HPV+ head and neck cancers 43
44 TG4001 Positive Phase 2b in HPV-associated CIN 2/3 Demonstration of statistically significant curative activity at 6 months PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 206 PATIENTS) in patients with cervical carcinoma in situ of high grade (2/3) Resolution (%) Viral clearance (%) Single agent TG4001 is active, and able P = P = HPV16 All Genotypes TG4001 monotherapy Placebo P = p = HPV16 All Genotypes to address HPV-related carcinomas Data represent a strong POC of active immunotherapy TG4001 was 5x superior in HPV16 patients compared to placebo to induce complete disease regression TG4001 showed an efficacy 4 fold superior compared to placebo regarding the viral clearance Clinical experience in 300+ subjects, demonstrating good safety profile Injection site reactions were the most common AE 44
45 Contact Lucie Larguier Director Corporate Communication and Investor Relations / larguier@transgene.fr / Transgene 400 Boulevard Gonthier d Andernach - Parc d Innovation - CS Illkirch Graffenstaden Cedex France Tél.: + 33 (0)
Virus-based immunotherapies to transform the fight against cancers and infectious diseases. September 2018 First Half 2018 & Business Update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases September 2018 First Half 2018 & Business Update Disclaimer This presentation contains forward-looking statements,
More informationVirus-based immunotherapies to transform the fight against cancers and infectious diseases. March 21, 2018 FY Results 2017 & Business update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases March 21, 2018 FY Results 2017 & Business update Disclaimer This presentation contains forward-looking statements,
More informationFirst half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed Seven active clinical trials: o First patients treated in four combination trials
More informationJefferies Healthcare Conference, London, November 19-20, Elisabetta Castelli PhD Director Investor Relations
Jefferies Healthcare Conference, London, November 19-20, 2014 Elisabetta Castelli PhD Director Investor Relations SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the
More informationViral-vector based immunotherapies to transform the fight against cancer and infectious diseases. January, 2019
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases January, 2019 Disclaimer This presentation contains forward-looking statements, which are subject to numerous
More informationVirus-based immunotherapies to transform the fight against solid tumors and infectious diseases. March 2019 Full Year Results 2018 & Business Update
Virus-based immunotherapies to transform the fight against solid tumors and infectious diseases March 2019 Full Year Results 2018 & Business Update Disclaimer This presentation contains forward-looking
More informationTransgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials Programs progressing in line with strategy Significant reduction of net loss: 12.2 million compared to
More informationTransgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
2017 Full-year results and business update Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses All clinical programs made progress o o 7 clinical
More informationTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy
Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy Parc d Innovation, Illkirch, France, March 22, 2010 Transgene (Euronext Paris: FR0005175080) details its
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationTG4010. Public Information
TG4010 Public Information 11 May 2017 Public Information 11 May 2017 Page 2 /7 ABBREVIATIONS DNA Deoxyribonucleic acid GMO Genetically modified organism IL2 Interleukin-2 IM Intramuscular IT Intratumoral
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationFirst Quarter 2018 Results
First Quarter 2018 Results 1 April 27, 2017 Investor call Q1 2017 April 27, 2018 First quarter and after period close highlights and significant events Strong progress in the MIV-818 project Successful
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationNews Release. Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab.
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationArming the patient s immune system to fight cancer. Q presentation
Arming the patient s immune system to fight cancer Q1 2017 presentation April 25 th 2017 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationNews Release. December 9, Not intended for UK-based media
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72-9591 Investor Relations: +49 6151 72-3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More information